Prognostic Value of KRAS Mutations in Codons 12 and 13 in South Egyptian Colorectal Cancer Patients
Journal Title: Journal of Cancer and Tumor International - Year 2015, Vol 2, Issue 4
Abstract
Aims: The aim of the study was to assess the frequency of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutation, perform clinicopathologic characterization of KRAS mutated colorectal cancer (CRC), evaluation of the prognostic significance of KRAS mutations and their influences on the outcome in patients with CRC after curative surgical resection. Patients and Methods: This study included 79 previously untreated CRC cases presented to South Egypt Cancer Institute from January 2011 to June 2013. Tumor samples were prospectively analyzed for KRAS mutations detection using DNA Clamp technique. Results: Genotyping revealed an overall mutation frequency of 31.6% in KRAS gene. 68% of the mutations were in codon 12 and 23% in codon 13. Patients with KRAS mutated CRC had statistically significant increase in the rate of local recurrence (P=.002) and distant metastases (P=.024) compared to patients with KRAS wild type CRC. There was statistically significant poorer 2-year disease free survival (DFS) (61.6% vs 86.2%, P=.01) and overall survival (OS) (83.1% vs 90.7%, P=0.04) in cases with KRAS mutated vs KRAS wild type CRC. Codon 13 was associated with statistically significant lower 2-year DFS (46.9% vs 81.4%, P=.008) and OS (62.5% vs 91.4%, P=.009) compared to cases without codon 13 KRAS mutation. Conclusion: The prognostic significance of KRAS mutation status regarding survival and treatment outcome in CRC might form the basis for more specific adjuvant therapy to improve survival.
Authors and Affiliations
Alia M. Attia, Hosny Badrawy, Hisham M. Hamza, Tarek M. Elsaba
Keywords
Related Articles
- EP ID EP242996
- DOI 10.9734/JCTI/2015/20417
- Views 85
- Downloads 0
Role of Oncogenes and Tumor Suppressors in Metabolic Reprogramming and Cancer Therapeutics: A Review
Recently there has been a renewed interest on the signaling pathways and metabolic changes in cancer cells. It is well known that there are several oncogenes and tumor suppressors that affect cancer metabolism and re-eng...
MiRNA and Target Oncogene Regulation in Triple Negative Breast Cancer: An Age, Ethnic and Environmental Related Neoplastic Event
Triple-negative breast cancer is a type of aggressive breast cancer without the immunohistochemical expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor-2; with poor prognos...
Could Monocytes Colonized by Circulating Epithelial Cells of the Prostate Gland be a Source of Metastasis of the Adenocarcinoma? A Hypothesis Based on a Previous Study
Background: Recently we reported the successful in vitro cultivation of prostatic epithelial and stromal cells from patients with benign prostatic hyperplasia and adenocarcinoma of the prostate by liquid biopsy. In that...
Serum Soluble CD25 in Hepatocellular Carcinoma, Shall We Able to Change the Natural History?
Background: Although hepatocellular carcinoma (HCC) is one of the most common malignancy related mortality worldwide, it can be curable if detected in early stages. Axiomatically, emergence of a new marker for early pred...
Current Discoveries and Management of Psammomatous Melanotic Schwannoma
Psammomatous melanotic schwannoma is a rare form of schwannoma that is distinct in terms of presentation, location, and nature compared to other types. This tumor is highly associated with Carney complex, but has also be...